Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2017

View Archived Issues

Galderma initiates phase II trial of NP-000888 for plaque and nail psoriasis

Signum Biosciences awarded NIAID grant to develop candidate for atopic dermatitis

The University of Nantes presents new antifungal/antiparasitic agents.

Catalyst Therapeutics identifies new bromodomain inhibitors

Phase II trial investigates gene therapy CYL-02 for locally advanced pancreatic cancer

U.S. orphan designations granted to atezolizumab, atezolizumab plus cobimetinib for melanoma

G100 given FDA orphan drug designation for follicular lymphoma

Versant Ventures announces launch of Jecure Therapeutics

Spotlight Innovation enters second Zika agreement with Florida State University

FDA approves Spiriva Respimat for use in children

NIH Blueprint Neurotherapeutics Network awards grant to Knopp Biosciences

Tracon Pharmaceuticals begins dosing in phase III TAPPAS study of TRC-105

Amygdala Neurosciences acquires ALDH2 inhibitor from Gilead

Capricor terminates natriuretic peptide receptor agonist license agreement with Mayo Clinic

High virologic response rates seen with bictegravir regimen in phase II trial

Phase III study of Lynparza meets primary endpoint in BRCA-mutated metastatic breast cancer

Five-marker methylation panel detected for ulcerative colitis-associated neoplasia

XBiotech's phase II study of MABp1 meets primary endpoint

Chugai seeks Japanese approval for atezolizumab for NSCLC

FDA accepts Mylan and Biocon's BLA for MYL-1401H for review

Clinical results with velmanase alfa in adults and children reported

Astellas Pharma describes novel MC4 receptor agonists

Allergan discloses new fMet-Leu-Phe/N-formyl peptide receptor 2 agonists

Phase I/II results of rAAV2/5-hNA-GLU in children with MPS IIIB presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.